Subscribe to RSS
DOI: 10.1055/s-0042-1748927
COVID-19 Associated Mucormycosis with Newly Diagnosed Diabetes Mellitus in Young Males – A Tertiary Care Experience
Abstract
Introduction Patients with a history of or active COVID-19 infection are predisposed to the development of opportunist bacterial and fungal infections. A rising incidence of a rare occurring fungal infection earlier, called mucormycosis, has been reported in abundance across the globe since March 2021, especially in India just as the second wave of COVID-19 began, caused by the trifecta of hyperglycemia (new-onset or exacerbation of pre-existing diabetes), oxygen therapy (invasive or noninvasive ventilation), and prolonged intake of steroids.
Objective The present study aimed at assessing the prevalence of post-COVID mucormycosis in males of younger age group and spread of rhino-orbital-cerebral mucormycosis (ROCM).
Methods A case-control study was performed over a period of 3 months among 60 male patients with confirmed diagnosis of mucormycosis. Individuals < 40 years old were included in the case group (n = 30), while those > 40 years old were included as controls (n = 30). Disease spread was assessed in three types of ROCM, that is, rhinomaxillary, rhino-orbital, and rhino-orbito-cerebral mucormycosis.
Results In the control group, the mean age was 48.47 years old, the mean HbA1c was 10.62 ± 1.88%, with most of them suffering from rhino-orbital mucormycosis. In the case group, the mean age was 31.57 years old, with a mean HbA1c of 10.11 ± 2.46%, and most patients had rhinomaxillary mucormycosis. The duration of steroid intake and mode of oxygen therapy were found to be significant in the severity of ROCM.
Conclusion Rising cases of post-COVID mucormycosis have brought to light the fatal consequences of prolonged use of steroids and oxygen therapy towards the development and spread of ROCM among young and middle-aged males.
Ethics Clearance
Clearance was obtained from the Institutional Ethics Committee.
Publication History
Received: 19 October 2021
Accepted: 20 March 2022
Article published online:
14 July 2022
© 2022. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Yang W, Cao Q, Qin L. et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect 2020; 80 (04) 388-393 DOI: 10.1016/j.jinf.2020.02.016.
- 2 Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India. Indian J Med Microbiol 2021; 39 (03) 380-383 DOI: 10.1016/j.ijmmb.2021.05.009.
- 3 Bashar MA. Mucormycosis infection in COVID-19 patients in India: An emerging lethal threat. J Clin Ophthalmol 2021; 5 (04) 433-434
- 4 Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NIA. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Med Mycol Case Rep 2020; 29: 22-24 DOI: 10.1016/j.mmcr.2020.05.008.
- 5 Badali H, Cañete-Gibas C, McCarthy D. et al. Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States. J Clin Microbiol 2021; 59 (09) e0123021 DOI: 10.1128/JCM.01230-21.
- 6 Ahmadikia K, Hashemi SJ, Khodavaisy S. et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses 2021; 64 (08) 798-808 DOI: 10.1111/myc.13256.
- 7 Jeong W, Keighley C, Wolfe R. et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect 2019; 25 (01) 26-34 DOI: 10.1016/j.cmi.2018.07.011.
- 8 Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42: 264.e5-264.e8
- 9 Chander J, Kaur M, Singla N. et al. Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India. J Fungi (Basel) 2018; 4 (02) 46 DOI: 10.3390/jof4020046.
- 10 Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med 2011; 32 (06) 693-702 DOI: 10.1055/s-0031-1295717.
- 11 Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15 (04) 102146 DOI: 10.1016/j.dsx.2021.05.019.
- 12 Chatterjee P. Mucormycosis in Context of the COVID-19 Pandemic. Acta Scientific Otolaryngology. 2021; 3 (06) 135-136
- 13 Mahalaxmi I, Jayaramayya K, Venkatesan D. et al. Mucormycosis: An opportunistic pathogen during COVID-19. Environ Res 2021; 201: 111643 DOI: 10.1016/j.envres.2021.111643.
- 14 Ajith A. Mucormycosis - The Dark Shadow of Coronavirus. Acta Scientific Otolaryngology. 2021; 3 (06) 101-102
- 15 Sabobeh T, Mushtaq K, Elsotouhy A, Ammar AA, Rashid S. Invasive rhinocerebral mucormycosis in a patient with liver cirrhosis leading to fatal massive stroke. Med Mycol Case Rep 2018; 22: 69-73
- 16 Cornely OA, Alastruey-Izquierdo A, Arenz D. et al; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and Research consortium. Lancet Infect Dis 2019; 19 (12) e405-e421
- 17 Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel) 2019; 5 (01) 26
- 18 Singh A, Gupta A. Surviving Mucormycosis: Impact on Psychological Well-Being and Quality of Life. Acta Scientific Otolaryngology. 2021; 3 (07) 90-92
- 19 Covid-19 Associated Mucormycosis.. National Centre for Disease Control Directorate General of Health Services, Government Of India. 2230179/2021/O/O IDSP-NCDC. June 2021. https://ncdc.gov.in/index1.php?lang=1&level=1&sublinkid=183&lid=97
- 20 Saini M. 100 days of mucormycosis in Haryana: 1719 new cases, 254 deaths. The times of India.. Aug 5, 2021 https://timesofindia.indiatimes.com/city/chandigarh/100-days-of-mucormycosis-in-haryana-1719-cases-254-deaths/articleshow/85054001.cms
- 21 Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope 1997; 107 (07) 855-862
- 22 Ismaiel WF, Abdelazim MH, Eldsoky I. et al. The impact of COVID-19 outbreak on the incidence of acute invasive fungal rhinosinusitis. Am J Otolaryngol 2021; 42 (06) 103080 DOI: 10.1016/j.amjoto.2021.103080.
- 23 John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi (Basel) 2021; 7 (04) 298
- 24 Papachristou S, Stamatiou I, Stoian AP, Papanas N. New-Onset Diabetes in COVID-19: Time to Frame Its Fearful Symmetry. Diabetes Ther 2021; 12 (02) 461-464 DOI: 10.1007/s13300-020-00988-7.
- 25 Vaezi A, Moazeni M, Rahimi MT, de Hoog S, Badali H. Mucormycosis in Iran: a systematic review. Mycoses 2016; 59 (07) 402-415 DOI: 10.1111/myc.12474.
- 26 Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus 2020; 12 (09) e10726 DOI: 10.7759/cureus.10726.
- 27 Klimko NN, Khostelidi SN, Volkova AG. et al. Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia. Mycoses 2014; 57 (Suppl. 03) 91-96 DOI: 10.1111/myc.12247.
- 28 Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature. J Mycol Med 2021; 31 (02) 101125 DOI: 10.1016/j.mycmed.2021.101125.
- 29 Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol 2021; 69 (04) 1002-1004